125 related articles for article (PubMed ID: 2950521)
1. Differential regulation of dopamine-D2 and serotonin-S2 receptors by chronic treatment with the serotonin-S2 antagonists, ritanserin, and setoperone.
Leysen JE; van Gompel P; Gommeren W; Laduron PM
Psychopharmacol Ser; 1987; 3():214-24. PubMed ID: 2950521
[No Abstract] [Full Text] [Related]
2. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.
Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA
Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361
[TBL] [Abstract][Full Text] [Related]
3. Opposite regulation of serotonin-S2 and dopamine-D2 receptors in rat brain following chronic receptor blockade.
Leysen JE; Van Gompel P; de Chaffoy de Courcelles D; Niemegeers CJ
J Recept Res; 1987; 7(1-4):223-39. PubMed ID: 3625598
[TBL] [Abstract][Full Text] [Related]
4. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
6. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
Cohen ML; Schenck KW; Kurz KD
J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
[TBL] [Abstract][Full Text] [Related]
7. Changes in dopamine2 and serotonin2 receptors in rat brain after long-term verapamil treatment: comparison of verapamil and lithium.
Baba S; Watanabe S
Jpn J Psychiatry Neurol; 1991 Mar; 45(1):95-102. PubMed ID: 1836506
[TBL] [Abstract][Full Text] [Related]
8. Lack of a difference between ketanserin and ritanserin in central vs. peripheral serotonin receptor antagonism.
Cohen ML; Bloomquist WL; Snoddy HD; Fuller RW
Life Sci; 1989; 45(13):1185-9. PubMed ID: 2507847
[TBL] [Abstract][Full Text] [Related]
9. [Role of serotonin and dopamine receptors in the mechanism of action of haloperidol and pirenperone].
Maĭmets MO; Vasar EE; Nurk AM; Allikmets LKh
Farmakol Toksikol; 1985; 48(2):15-8. PubMed ID: 3996566
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D2 receptors in the striatum and frontal cortex following chronic administration of haloperidol.
Liskowsky DR; Potter LT
Neuropharmacology; 1987 May; 26(5):481-3. PubMed ID: 2955242
[TBL] [Abstract][Full Text] [Related]
11. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
[TBL] [Abstract][Full Text] [Related]
12. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
Awouters F; Niemegeers CJ; Megens AA; Janssen PA
J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
[TBL] [Abstract][Full Text] [Related]
13. Action of serotonin in the medial prefrontal cortex: mediation by serotonin3-like receptors.
Ashby CR; Edwards E; Wang RY
Synapse; 1992 Jan; 10(1):7-15. PubMed ID: 1536032
[TBL] [Abstract][Full Text] [Related]
14. Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.
Hamik A; Peroutka SJ
Cancer Chemother Pharmacol; 1989; 24(5):307-10. PubMed ID: 2527092
[TBL] [Abstract][Full Text] [Related]
15. Effects of ritanserin on haloperidol-induced dopamine (D2) receptor up-regulation in the rat.
Szczepanik AM; Wilmot CA
Neurosci Lett; 1997 Aug; 231(2):91-4. PubMed ID: 9291148
[TBL] [Abstract][Full Text] [Related]
16. Receptor interactions of dopamine and serotonin antagonists: binding in vitro and in vivo and receptor regulation.
Leysen JE; Gommeren W; Janssen PF; Van Gompel P; Janssen PA
Psychopharmacol Ser; 1988; 5():12-26. PubMed ID: 3045796
[TBL] [Abstract][Full Text] [Related]
17. Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding.
Koulu M; Lappalainen J; Hietala J; Sjöholm B
Psychopharmacology (Berl); 1990; 101(2):168-71. PubMed ID: 2140903
[TBL] [Abstract][Full Text] [Related]
18. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
Saller CF; Czupryna MJ; Salama AI
J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636
[TBL] [Abstract][Full Text] [Related]
19. D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2.
Hatano K; Ishiwata K; Kawashima K; Hatazawa J; Itoh M; Ido T
J Nucl Med; 1989 Apr; 30(4):515-22. PubMed ID: 2567779
[TBL] [Abstract][Full Text] [Related]
20. Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action.
Meltzer HY; Zhang Y; Stockmeier CA
Eur J Pharmacol; 1992 May; 216(1):67-71. PubMed ID: 1388121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
